Founded in 2017, HDT Bio is dedicated to pioneering RNA vaccines and therapeutics through innovative research. The company focuses on developing advanced RNA vaccine products aimed at treating and preventing infectious diseases and cancers. Utilizing its proprietary LION™ technology, HDT Bio offers solutions with enhanced safety, potency, durability, and manufacturing efficiency. Their core mission is to redefine the global vaccine landscape by leveraging cutting-edge RNA technology.
Notable figures associated with HDT Bio include leading scientists and industry experts who drive the company's research and development efforts. The company has attracted significant attention from investors interested in transformative healthcare technologies. Key achievements include advancing their repRNA vaccine platform to clinical stages, demonstrating potential in both infectious disease prevention and cancer treatment. HDT Bio's impact is marked by its contributions to the field of RNA therapeutics, positioning itself as a significant player in the biotech industry.
